RNA Interference With Zilebesiran for Mild to Moderate Hypertension

This phase 2 randomized trial examines the antihypertensive efficacy and safety of different zilebesiran dosing regimens.

Related Keywords

Ukraine ,Chicago ,Illinois ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Pennsylvania ,Canada ,Philadelphia ,University Of Chicago ,Helsinki ,Eteläuomen Läi ,Finland ,Maryland ,American ,Eli Lilly ,Vifor Pharma ,Pharmagenesis Cardiff ,Georgel Bakris ,Pfizer ,Boehringer Ingelheim ,Novartis ,American Heart Association Comprehensive Hypertension Center ,Novo Nordisk ,International Conference On Harmonization ,Department Of Medicine ,American Heart Association Scientific Sessions ,Study Group ,Group Information ,University Of Chicago Medicine ,Glaxosmithkline ,Recor Medical Inc ,Alnylam Pharmaceuticals ,Astrazeneca ,Amgen ,Ablative Solutions Inc ,Good Clinical Practice ,International Conference ,Renal Disease ,Medical Dictionary ,Regulatory Activities ,End Point ,Secondary End Points ,Bend Points ,Chicago Medicine ,Maryland Ave ,Interest Disclosures ,Applied Therapeutics ,Axon Therapeutics ,Avidity Biopharma ,Good Publication Practice ,